Table 3.
Statin Side Effect Profile
| Type of Event | No. of Studies | Participants on Study Drug (Placebo) | No. With Adverse Event (Placebo) | RR or OR (95% CI) |
|---|---|---|---|---|
| Total adverse events | 12 | 20 718 (19 998) | 5748 (5090) | RR 1.00 (0.97–1.03) |
| Stopped treatment | 9 | 11 054 (10 588) | 940 (973) | OR 0.86 (0.65–1.12) |
| Myalgia | 9 | 19 396 (18 542) | 1847 (1704) | RR 1.03 (0.97–1.09) |
| Rhabdomyolysis | 6 | 19 410 (19 058) | 3 (3) | RR 1.00 (0.23–4.38) |
| DM | 2 | 12 205 (12 202) | 342 (290) | OR 1.18 (1.01–1.39) |
| Elevated liver enzymes | 10 | 20 420 (19 674) | 476 (472) | RR 1.16 (0.87–1.54) |
| Cancer | 11 | 19 789 (18 950) | 1180 (1075) | RR 1.01 (0.93–1.10) |
Abbreviations: CI, confidence interval; DM, diabetes mellitus; OR, odds ratio; RR, relative risk.
Data are from the 2013 Cochrane meta‐analysis.23